[Federal Register Volume 63, Number 145 (Wednesday, July 29, 1998)] [Notices] [Pages 40543-40544] From the Federal Register Online via the Government Publishing Office [www.gpo.gov] [FR Doc No: 98-20174] ----------------------------------------------------------------------- DEPARTMENT OF JUSTICE Drug Enforcement Administration Manufacturer of Controlled Substances; Application Pursuant to Sec. 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on May 12, 1998, Novartis Pharmaceuticals Corp., Regulatory Compliance, 556 Morris Avenue, Summit, New Jersey 07901, made application by renewal to the Drug Enforcement Administration (DEA) for registration as a bulk manufacturer of the Schedule II controlled substance methylphenidate (1724). The firm plans to manufacture finished product for distribution to its customers Any other such applicant and any person who is presently registered with DEA to manufacture such substances may file comments or objections to the issuance of the proposed registered. Any such comments or objections may be addressed, in quintuplicate, to the Deputy Assistant Administor, Office of Diversion Control, Drug Enforcement [[Page 40544]] Administration United States Department of Justice, Washington, D.C. 20537, Attention: DEA Federal Register Representative (CCR), and must be filed no later than September 28, 1998. Dated: July 16, 1998. John H. King, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. 98-20174 Filed 7-28-98; 8:45 am] BILLING CODE 4410-09-M